|
|
ASH 2011: Dr. Usmani - Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol
Saad Usmani, MD, FACP
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA
|
|
|
back
print
related articles
Be the first to comment